Early-onset dementia and risk of hip fracture and major osteoporotic fractures.
cholinesterase inhibitors
database
early‐onset dementia
fractures
osteoporosis
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
revised:
26
02
2024
received:
09
11
2023
accepted:
03
03
2024
medline:
2
4
2024
pubmed:
2
4
2024
entrez:
1
4
2024
Statut:
aheadofprint
Résumé
There is limited knowledge about early-onset dementia (EOD) on fracture risk. Individuals ages 50 to 64 were identified from the National Database of Health Insurance Claims and Specific Health Checkups of Japan (2012 to 2019). The association between EOD and fractures and the association between cholinesterase inhibitors for EOD and fractures were evaluated using logistic regression analyses. We identified 13,614 EOD patients and 9,144,560 cognitively healthy individuals. The analysis revealed that EOD was associated with an increased risk of hip fractures (adjusted odds ratio, 95% confidence interval: 8.79, 7.37-10.48), vertebral fractures (1.73, 1.48-2.01), and major osteoporotic fractures (2.05, 1.83-2.30) over 3 years. The use of cholinesterase inhibitors was significantly associated with a reduction in hip fractures among EOD patients (0.28, 0.11-0.69). EOD patients have a higher risk of osteoporotic fractures than cognitively healthy individuals. The use of cholinesterase inhibitors may reduce the risk of hip fracture among EOD patients. It is unknown whether early-onset dementia (EOD) increases the risk of fractures. We identified 13,614 individuals with EOD using a nationwide administrative database. Patients with EOD have a higher risk of hip, vertebral, and major osteoporotic fractures. The use of cholinesterase inhibitors may reduce hip fracture among patients with EOD.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Ministry of Health, Labor and Welfare, Japan
Organisme : Pfizer Health Research Foundation
Organisme : Taiju Life Social Welfare Foundation
Organisme : Japan Osteoporosis Foundation
Informations de copyright
© 2024 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Rossor MN, Fox NC, Mummery CJ, et al. The diagnosis of young‐onset dementia. Lancet Neurol. 2010;9:793‐806. doi:10.1016/S1474‐4422(10)70159‐9
Edahiro A, Miyamae F, Taga T, et al. Incidence and distribution of subtypes of early‐onset dementia in Japan: a nationwide analysis based on annual performance reports of the Medical Centers for Dementia. Geriatr Gerontol Int. 2020;20:1050‐1055. doi:10.1111/ggi.14043
Ikejima C, Ikeda M, Hashimoto M, et al. Multicenter population‐based study on the prevalence of early onset dementia in Japan: vascular dementia as its prominent cause. Psychiatry Clin Neurosci. 2014;68:216‐224. doi:10.1111/pcn.12127
Awata S, Edahiro A, Arai T, et al. Prevalence and subtype distribution of early‐onset dementia in Japan. Psychogeriatrics. 2020;20:817‐823. doi:10.1111/psyg.12596
Hendriks S, Peetoom K, Bakker C, et al. Global Prevalence of young‐onset dementia: a systematic review and meta‐analysis. JAMA Neurol. 2021;78:1080‐1090. doi:10.1001/jamaneurol.2021.2161
Hsu B, Bleicher K, Waite LM, et al. Community‐dwelling older men with dementia are at high risk of hip fracture, but not any other fracture: the Concord Health and Aging in Men Project. Geriatr Gerontol Int. 2018;18:1479‐1484. doi:10.1111/ggi.13516
Wang HK, Hung CM, Lin SH, et al. Increased risk of hip fractures in patients with dementia: a nationwide population‐based study. BMC Neurol. 2014;14:175. doi:10.1186/s12883‐014‐0175‐2
Hiramatsu K, Barrett A, Miyata Y. PhRMA Japan Medical Affairs Committee Working Group 1. Current status, challenges, and future perspectives of real‐world data and real‐world evidence in Japan. Drugs Real World Outcomes. 2021;8:459‐480. doi:10.1007/s40801‐021‐00266‐3
Hirose N, Ishimaru M, Morita K, et al. A review of studies using the Japanese National Database of Health Insurance Claims and Specific Health Checkups. Ann Clin Epidemiol. 2020;2:13‐26.
Japan Osteoporosis Society. Guidelines on the prevention and treatment of osteoporosis 2015. The committee for development of the guidelines on the prevention and treatment of osteoporosis. (in Japanese). 2015. Accessed November 8, 2023. www.josteo.com/ja/guideline/doc/15_1.pdf
Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185‐1194. doi:10.1359/JBMR.050304
Leslie WD, Schousboe JT, Morin SN, et al. Fracture risk following high‐trauma versus low‐trauma fracture: a registry‐based cohort study. Osteoporos Int. 2020;31:1059‐1067. doi:10.1007/s00198‐019‐05274‐2
Kanis J, Johnell O, Laet CD, et al. A meta‐analysis of previous fracture and subsequent fracture risk. Bone. 2004;35:375‐382. doi:10.1016/j.bone.2004.03.024
Hosoi T, Yakabe M, Matsumoto S, et al. Relationship between antidementia medication and fracture prevention in patients with Alzheimer's dementia using a nationwide health insurance claims database. Sci Rep. 2023;13:6893. doi:10.1038/s41598‐023‐34173‐0
Tan B, Fox S, Kruger C, Lynch M, Shanagher D, Timmons S. Investigating the healthcare utilisation and other support needs of people with young‐onset dementia. Maturitas. 2019;122:31‐34. doi:10.1016/j.maturitas.2019.01.003
Shang L, Dong L, Huang X, et al. Comorbidity of dementia: a cross‐sectional study of PUMCH Dementia Cohort. J Alzheimers Dis. 2024;97:1313‐1322. doi:10.3233/JAD‐231025
Tellechea P, Pujol N, Esteve‐Belloch P, et al. Early‐ and late‐onset Alzheimer disease: are they the same entity? Neurologia (Engl Ed). 2018;33:244‐253. doi:10.1016/j.nrl.2015.08.002
Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One. 2009;4:e5521. doi:10.1371/journal.pone.0005521
Nyul‐Toth A, DelFavero J, Mukli P, et al. Early manifestation of gait alterations in the Tg2576 mouse model of Alzheimer's disease. Geroscience. 2021;43:1947‐1957. doi:10.1007/s11357‐021‐00401‐6
Giau VV, Bagyinszky E, Youn YC, An SSA, Kim S. APP, PSEN1, and PSEN2 mutations in Asian patients with early‐onset Alzheimer disease. Int J Mol Sci. 2019;20:4757. doi:10.3390/ijms20194757
Allan LM, Ballard CG, Burn DJ, Kenny RA. Prevalence and severity of gait disorders in Alzheimer's and non‐Alzheimer's dementias. J Am Geriatr Soc. 2005;53:1681‐1687. doi:10.1111/j.1532‐5415.2005.53552.x
Joza S, Camicioli R, Ba F. Falls in synucleinopathies. Can J Neurol Sci. 2020;47:30‐43. doi:10.1017/cjn.2019.287
Zhao Y, Shen L, Ji HF. Alzheimer's disease and risk of hip fracture: a meta‐analysis study. Scientific World Journal. 2012;2012:872173. doi:10.1100/2012/872173
Bliuc D, Tran T, Adachi JD, et al. Cognitive decline is associated with an accelerated rate of bone loss and increased fracture risk in women: a prospective study from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res. 2021;36:2106‐2115. doi:10.1002/jbmr.4402
Matsumoto S, Tamiya H, Yamana H, et al. Association between the type of hypnotic drug and in‐hospital fractures in older patients with neurocognitive disorders: a case‐control study using a nationwide database. Geriatr Gerontol Int. 2023;23:500‐505. doi:10.1111/ggi.14600
Lin FY, Chen PC, Liao CH, Hsieh YW, Sung FC. Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep. 2014;37:673‐679. doi:10.5665/sleep.3566
Irwin MR, Vitiello MV. Implications of sleep disturbance and inflammation for Alzheimer's disease dementia. Lancet Neurol. 2019;18:296‐306. doi:10.1016/S1474‐4422(18)30450‐2
Kunz D, Oster H, Rawashdeh O, Neumann WJ, Münte T, Berg D. Sleep and circadian rhythms in α‐synucleinopathies‐Perspectives for disease modification. Acta Physiol (Oxf). 2023;238:e13966. doi:10.1111/apha.13966
Bakken MS, Schjøtt J, Engeland A, Engesaeter LB, Ruths S. Antipsychotic drugs and risk of hip fracture in people aged 60 and older in Norway. J Am Geriatr Soc. 2016;64:1203‐1209. doi:10.1111/jgs.14162
Brännström J, Lövheim H, Gustafson Y, Nordström P. Antipsychotic Drugs and hip fracture: associations before and after the initiation of treatment. J Am Med Dir Assoc. 2020;21:1636‐1642.e6. doi:10.1016/j.jamda.2020.06.047
Azimi Manavi B, Stuart AL, Pasco JA, et al. Antipsychotic medication use and fracture: a case‐control study. Sci Rep. 2023;13:13709. doi:10.1038/s41598‐023‐40762‐w
Buckley JS, Salpeter SR. A risk‐benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging. 2015;32:453‐467. doi:10.1007/s40266‐015‐0266‐9
Takusari E, Sakata K, Hashimoto T, Fukushima Y, Nakamura T, Orimo H. Trends in hip fracture incidence in Japan: estimates based on nationwide hip fracture surveys from 1992 to 2017. JBMR Plus. 2020;5:e10428. doi:10.1002/jbm4.10428
Gregson CL, Armstrong DJ, Bowden J, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2022;17:58. doi:10.1007/s11657‐022‐01061‐5
Population estimation by Ministry of Internal Affairs and Communications (in Japanese). Accessed November 8, 2023. www.stat.go.jp/data/jinsui/2012np/pdf/2012np.pdf
Report on Regional Public Health Services and Health Promotion Services by Ministry of Health, Labour and Welfare for the Fiscal Year 2021, (in Japanese). Accessed November 8, 2023. www.mhlw.go.jp/toukei/saikin/hw/c‐hoken/21/dl/kekka2.pdf
Gerritsen AAJ, Bakker C, Verhey FRJ, et al. Survival and life‐expectancy in a young‐onset dementia cohort with six years of follow‐up: the NeedYD‐study. Int Psychogeriatr. 2019;31:1781‐1789. doi:10.1017/S1041610219000152